147 results about "Vaccine product" patented technology

The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

The invention relates to a preparation method and a product of an H9N2 subtype avian influenza inactivated vaccine. The technical points of the invention mainly relate to the screening, the determination and the domestication of a virus-adapted cell line, the primary amplification cultivation and the continuous cultivation of a virus-adapted cell, the preparation of virus fluid by virus-inoculated culture and the preparation of final inactivated vaccine products. Firstly, the invention avoids the virus propagating method using a large amount of chick embryos in the avian influenza production at present, thereby avoiding the problem of biological potential safety hazards, and overcoming the problem that the mass production of vaccines is enslaved to the supply of the chick embryos; secondly, the invention provides a safe, continuous and closed cell culture virus production method, is used for the preparation of the H9N2 subtype avian influenza inactivated vaccine, enables the use of the cell culture method, and can simultaneously produce high-titer viruses to meet the requirements for the immunological production; and finally, the vaccine production method of the invention is simple and fast, thereby realizing the fast vaccine supply at the epidemic situation.

The invention relates to a recombinant nerve putrescence virus protein vaccine, the nucleic acid sequence coding the recombinant protein, and the use of the recombinant protein in preparing fish use vaccine product for nerve putrescence viruses resistance. Wherein the cDNA of the capsid nucleocapsid for the grouper nerve putrescence viruses is utilized to obtain the polypeptide recombinant proteins through DNA recombination process and pronucleus expression method.

The invention provides a novel lyophilized mite allergen vaccine and a preparation method thereof. The vaccine is prepared by mixing and lyophilizing mite allergen activated protein, a lyophilization protective agent and phosphate buffer solution with pH value of 7.0-8.5 based on the weight ratio of 1:(100-1000):(70-140). Compared with the traditional water preparation, glycerol preparation and preparation containing an aluminum hydroxide adjuvant of the mite allergen vaccine, the lyophilized mite allergen vaccine overcomes use inconvenience of the glycerol preparation, instability of the water preparation and side effects resulting from the preparation containing the aluminum hydroxide adjuvant, thus providing an efficient vaccine product with good stability and good safety for patients allergic to dust mites.

The present invention provides a thermochromic material bar code tag and a reading method thereof. The thermochromic material bar code tag is a tag configured to mark vaccine product information and storage state, and comprises a thermochromic area and an area comprising product information, and the thermochromic area is formed by VVM (Vaccine Vial Monitor) thermal tags. A reading device is employed to read the thermochromic material bar code tag to achieve one-step reading of the product production information and the storage state information, accelerate the input process of vaccine cold chain transportation and cold chain information, improve the input accuracy and avoid the problem that workers are fatigable and low in efficiency in a batch reading mode.

The invention provides a method for removing residual DNA in a hydrophobia vaccine product by utilizing ultrasound combined with EDTA solution. The method solves the problems that a method for extracting hydrophobia vaccine through concentration, purification and the like can only remove dissociative DNA in a certain percentage and cannot remove host DNA combined with antigen protein and clinical adverse reactions commonly occur. The method has main points of: adding the EDTA solution into hydrophobia vaccine concentrate; performing ultrasonic treatment on the hydrophobia vaccine by using ultrasonic wave to make the host DNA broken more easily under the action of the ultrasound; and removing the host DNA through chromatography and purification. The method has the advantages that: on the premise of ensuring the valence of the vaccine, the quality of a vaccine product is improved, mass hybrid protein and the host DNA are removed so that the residual DNA content of the vaccine product is less than 100 pg / dose, and the quality problem in the hydrophobia vaccine industry at present is solved.

The invention provides a vaccine product with respectively packaged freeze-dried vaccine and dilute solution thereof and method for preparing the dilute solution, which aims to solve the problem that the patent No. 93105862.7 records a vaccine in liquid state made by the combination of polyinosinic cytidilic acid containing kanamycin and calcium ions with lyssa virus antigen, both of which are in liquid states, has a guarantee period that is strictly limited to result in the limitation of the application of the product; and the method for preparing the adjuvant of polyinosinic cytidilic acid containing kanamycin and calcium ions is not disclosed in the patent No. 93105862.7. The invention has the following essentials: (1) freeze-dried vaccine and dilute solution thereof are respectively packaged, and the dilute solution is the polyinosinic cytidilic acid containing kanamycin and calcium ions; (2) the method for preparing the dilute solution. The invention overcomes the defect that the freeze-dried vaccine can not use PIKA adjuvant, and widens the practical application range of the PIKA adjuvant.

The invention provides a novel lyophilized mite allergen vaccine and a preparation method thereof. The vaccine is prepared by mixing and lyophilizing mite allergen activated protein, a lyophilization protective agent and phosphate buffer solution with pH value of 7.0-8.5 based on the weight ratio of 1:(100-1000):(70-140). Compared with the traditional water preparation, glycerol preparation and preparation containing an aluminum hydroxide adjuvant of the mite allergen vaccine, the lyophilized mite allergen vaccine overcomes use inconvenience of the glycerol preparation, instability of the water preparation and side effects resulting from the preparation containing the aluminum hydroxide adjuvant, thus providing an efficient vaccine product with good stability and good safety for patients allergic to dust mites.